Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension

Essential Hypertension Clinical Trial

Official title:

Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00380289
• Other study ID #: OGTT1
• Status: Recruiting
• Phase: N/A
• First received: September 22, 2006
• Last updated: September 22, 2006
• Start date: September 2006

Study information

• Verified date: September 2006
• Source: University of Cambridge
• Contact: Professor MJ Brown, MA MSC MD FRCP
• Phone: 01223 762577 (UK)
• Email: mjb14[@]medschl.cam.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?

Description:

We will be comparing the two most commonly used drugs to treat hypertension, atenolol and bendrofluazide, in patients for whom the drugs (and the doses to be used) are licenced.

We propose an initial open label pilot study of 10-12 patients to confirm final doses to be tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses selected. The pilot study will also be used to confirm sample size calculations for the main study.The protocol for the pilot study will be identical to the main study, but there will not be a placebo phase and the treatment will not be blinded.

The main study will be double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher dose stated half way through each dosing period. There will be a 1 month placebo wash-out between each dosing period.

At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 0.5, 1 and 2 hours.

Blood pressure will be measured at each study visit using an Omron machine. The patients will also be given a blood pressure machine to take home and will be asked to measure and record their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the patient will be asked to contact study staff. If the blood pressure remains over 160/110 for two measurements, then another antihypertensive therapy may be commenced, or the patient withdrawn from the study. If blood pressure is < 110/70 mmHg with symptoms then a decision may be made to terminate their participation in the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Volunteers will be aged 18-75 years.

• Hypertension- either

• untreated, BP 140-170/90-110

• treated for over 1 month with drugs other than beta blockers or diuretic and BP>140/85

• treated for over 1 month with drugs other than beta blockers or diuretic and BP<140/85 and patient willing to change medication for eight months.

Exclusion criteria:

• Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control.

• Any patient who is intolerant of these medications will be excluded from the study.

• Patients with gout, asthma or any other contraindications to the study drugs will be excluded.

• Women of child bearing age not using contraception.

• Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer)

• Volunteers not able to give informed consent

• Patients with diabetes

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Drug:
• Thiazide and beta blocker

Locations

Country	Name	City	State
United Kingdom	Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital	Cambridge

Sponsors (2)

Lead Sponsor	Collaborator
University of Cambridge	Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?
Secondary	Do patients show a similar change in glucose tolerance after thiazide or beta blocker therapy?
Secondary	Does the combination of drugs cause a greater reduction in glucose tolerance than expected from the response to each drug taken alone?